The New York Times Health section today featured a study published in the IJTLD that found the survival of patients with TB and HIV/AIDS improved when ART is started immediately.
Patients who have multidrug-resistant tuberculosis and HIV/AIDS are more likely to live if they receive antiretroviral treatment rapidly after the initiation of anti-tuberculosis treatment, according to a new study published in the International Journal of Tuberculosis and Lung Disease. The study was cited in The New York Times Health section on 18 February 2014, reflecting the widespread interest in effective TB-HIV treatment.
The study, which was conducted by Dr Gerald Friedland of the Yale University School of Medicine and colleagues from the Centre for the AIDS Programme of Research in South Africa (CAPRISA), brings added weight to the importance of getting patients on to antiretroviral treatment within the first few weeks of starting anti-TB treatment.
Read the New York Times article: http://tinyurl.com/n84q573
Read the study (available as pay-per-view; free to Union members and IJTLD subscribers)
Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial
http://www.ingentaconnect.com/content/iuatld/ijtld/2014/00000018/00000002/art00005